Alpha Tau Medical Ltd. DRTS
13.36 USD -0.66 (-4.71%)
At closeNov 12, 2026, 6:21 PM EST
13.37 +0.01 +0.07%
After hours · Nov 12, 6:21 PM ET
13.15 Day range 13.92
3.43 52-week range 15.79
- YTD
- +169.90%
- 1 year
- +236.52%
News
globenewswire.com Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial JERUSALEM, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today…
benzinga.com This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded RSG, AAPL, MRCY, DK and DRTS, revising price targets, including AAPL to $425 and DRTS to $22.
benzinga.com Piper Sandler Upgrades Alpha Tau Medical to Overweight, Raises Price Target to $22 Piper Sandler analyst Allison Bratzel upgrades Alpha Tau Medical (NASDAQ:DRTS) from Neutral to Overweight and raises the price target from $8 to $22.
benzinga.com Alpha Tau Medical To Join TASE’s TA-90 and TA-125 Indices On November 5, 2026 Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdingsTA-125 tracks the 125 largest and most prominent companies on the TASEJERUSALEM, Oct. 29, 2026…
globenewswire.com Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026…
benzinga.com Alpha Tau Medical Inks MoU With Samsung Medical Center In Seoul Regarding Potential Clinical Study In Pancreatic Cancer Patients Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the signing of an MOU in Seoul, South Korea,…
globenewswire.com Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea - MOU relates to a potential clinical trial in South Korea, Alpha DaRT's first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.
benzinga.com Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration…
globenewswire.com Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting - FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua…
globenewswire.com Alpha Tau to Participate in October Investor Conferences JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,…
seekingalpha.com Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's…
seekingalpha.com Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients…- benzinga.com Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30 Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $17 to $30.
globenewswire.com Alpha Tau to Participate in September Investor Conferences JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
globenewswire.com Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions - IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12…
defenseworld.net PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two…
benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16 HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.- benzinga.com Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses…
globenewswire.com Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,…- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients Response RateAmong evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate (i.e., systemic complete response plus partial response) of 100%, including…
globenewswire.com Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with…
defenseworld.net Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) shares rose 7.1% on Friday. The company traded as high as $12.53 and last traded at $12.7280. 196,591 shares were traded during trading, a…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS)…
benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
benzinga.com Alpha Tau Medical Treats First Patient In ADMIRE Study, Clinical Trial Evaluating Intratumoral Alpha DaRT For Immunocompromised Patients With Recurrent Cutaneous Squamous Cell Carcinoma - The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which…
globenewswire.com Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
zacks.com New Strong Sell Stocks for July 7th AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
zacks.com New Strong Sell Stocks for July 2nd DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
gurufocus.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation- benzinga.com Alpha Tau Medical Announces Success Treatment With Alpha DaRT Of First Glioblastoma Patient In Israel Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the successful treatment with Alpha DaRT of the…
globenewswire.com Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah Medical Center in Israel
seekingalpha.com Alpha Tau Medical: A Lot Of Shots On Goal Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with strong recent clinical and partnership momentum. DRTS's innovative and patented "Alpha DaRT"…- benzinga.com Alpha Tau Medical Receives FDA Clearance To Proceed With Enrollment Of Final Seven Patients In U.S. REGAIN Trial - Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining…
globenewswire.com Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Control- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
benzinga.com Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $17 Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and raises the price target from $15 to $17.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELYB, NN, BVC, MX, ECX, DRTS, RZLT, SYRE, TGTX.- benzinga.com Alpha Tau Medical and Tolmar Form U.S. Prostate Cancer Partnership To Commercialize Alpha DaRT Therapy With Exclusive Rights And Long-Term Revenue Sharing Deal - Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Alpha Tau Medical Presents Overall Survival, Safety Results From Pooled Analysis Of Three Prospective Phase I/II Clinical Studies Evaluating EUS-Guided Intratumoral Alpha Dart Treatment In PDAC Patients At 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey -- Pooled analysis of…
- benzinga.com Barclays Initiates Coverage On Alpha Tau Medical with Overweight Rating, Announces Price Target of $15 Barclays analyst Lukas Shumway initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Overweight rating and announces Price Target of $15.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
- benzinga.com Piper Sandler Maintains Neutral on Alpha Tau Medical, Raises Price Target to $8 Piper Sandler analyst Jason Bednar maintains Alpha Tau Medical (NASDAQ:DRTS) with a Neutral and raises the price target from $5 to $8.
benzinga.com CORRECTION: Alpha Tau Medical Q1 EPS $(0.26) Misses $(0.12) Estimate Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.12) by 116.67 percent. This is a 116.67 percent decrease over losses…- benzinga.com Ladenburg Thalmann Maintains Buy on Alpha Tau Medical, Raises Price Target to $14 Ladenburg Thalmann analyst Jeff Cohen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $12 to $14.
- benzinga.com HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $15 HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $12 to $15.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session